Denver, CONCT07503808Now EnrollingIRB Ready

Esophageal Squamous Cell Carcinoma Clinical Trial in Denver, CO

Access cutting-edge esophageal squamous cell carcinoma treatment through this clinical trial at a research site in Denver. Study-provided care at no cost to qualified participants.

Sponsored by IDEAYA Biosciences

Quick Self-Assessment

See if you qualify for this Denver location

Preparing your pre-screening questions…

Expert Care in Denver

Access esophageal squamous cell carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related esophageal squamous cell carcinoma treatment provided free

Apply for This Denver Location

Check if you qualify for this esophageal squamous cell carcinoma clinical trial in Denver, CO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Denver

    Convenient for CO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Denver site if eligible
  4. 4Begin participation

About This Esophageal Squamous Cell Carcinoma Study in Denver

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

Sponsor: IDEAYA Biosciences

Who Can Participate

Inclusion Criteria

Participant must be at least 18 years of age or the age of maturity per local regulations
Participants with advanced recurrent or metastatic solid tumors expressing B7-H3 and PTK7 in the following indications: NSCLC, ESCC, endometrial cancer, HGSOC, HNSCC, TNBC (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 \[HER2\] negative), CRC, and CRPC who have radiologically progressed or recurred on at least one line of therapy or is intolerant to additional effective standard therapies.
Archival tissue sample for testing
Measurable disease
Have Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
Have adequate bone marrow and organ function.
Able to comply with contraceptive/barrier requirements

Exclusion Criteria

Known symptomatic brain metastases or leptomeningeal metastasis
Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose.
Have uncontrolled tumor-associated pain
Have clinically significant cardiac abnormalities and/or cerebrovascular disease (stroke) within 6 months before the first dose
Active uncontrolled infection
Have history of interstitial pneumonitis, current noninfectious pneumonitis requiring steroid therapy; known or suspected interstitial pneumonitis as seen on screening imaging; other moderate to severe lung diseases seriously affecting respiratory function within 3 months before the first dose.
Have history of severe infections within 4 weeks prior to the start of study treatment, including but not limited to bacteremia, severe pneumonia, or other serious infectious complications requiring hospitalization.
Have history of immunodeficiency, with a positive human immunodeficiency virus (HIV) test at screening.
Participants with known or suspected viral hepatitis
Have history of active tuberculosis within 1 year before enrollment
If participants had adverse reactions to previous antitumor treatment that have not recovered to guidelines of CTCAE Grade ≤ 1 and Grade 2 peripheral neurological symptoms
Have received chemotherapy within 3 weeks of first dose of IMP; immunotherapy or biologic targeted antitumor treatments within 3 weeks before the first dose of IMP or other investigational products within 4 weeks of first dose of IMP
Administration of any of the following
Current use or anticipated need for food or drugs that are known strong CYP3A4/5 inhibitors or inducers
Have prior treatment with B7-H3 or PTK7 antibody-drug conjugate (ADC).
Have prior treatment with a topoisomerase I inhibitor (TOP1i), including an ADC with a TOP1i payload, within 6 months of first dose of IMP
Have received radiotherapy within 2 weeks prior to study entry
Have undergone major surgery or trauma within 4 weeks prior to study entry.
Have received live attenuated vaccine within 28 days prior to the first dose or are expected to receive live attenuated vaccine during the study treatment.
Female participants who are pregnant, lactating, or planning to become pregnant during the study period to 7 months after the last dose of IMP.
Are known to be allergic to any component or excipient of the IMP product or have a history of severe allergic reactions to other monoclonal antibody/fusion protein drugs.
Participants with complications in the eye including ulcers in the eye, and severe dry eye

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Denver?

Yes, this clinical trial (NCT07503808) has an active research site in Denver, CO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Esophageal Squamous Cell Carcinoma Treatment Options in Denver, CO

If you're searching for esophageal squamous cell carcinoma treatment options in Denver, CO, this clinical trial (NCT07503808) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Denver research site is actively enrolling participants for this clinical trial. You'll receive care from experienced esophageal squamous cell carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all esophageal squamous cell carcinoma clinical trials near you to find additional studies recruiting in your area.

More Esophageal Cancer Trials in Denver, CO

See all esophageal cancer clinical trials recruiting in Denver — not just this study.

Browse Esophageal Cancer Trials in Denver →

Browse More Trials by Condition

Esophageal Cancer TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Denver?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Denver, CO